Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604682 · ClinicalTrials.gov registry record · Phase 2
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00604682 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 19 participants.
The verdict
NCT00604682, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque type psoriasis.
Interventions
- DRUG CC10004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-01-01 |
| Est. Completion | 2005-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00604682
The ClinicalTrials.gov registry entry for NCT00604682 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC10004 is the first listed.
NCT00604682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00604682 about?
NCT00604682 is a clinical study titled "Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis". Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque type psoriasis.
What is the current status of trial NCT00604682?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2005-01-01. Estimated completion is 2005-12-01.
What interventions are being tested in trial NCT00604682?
The interventions under investigation include: CC10004 (DRUG).
Who is sponsoring clinical trial NCT00604682?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.